Harvoni is a combination of ledipasvir and sofosbuvir and is one of the DAA regimens used to treat hepatitis C. Its specific use depends on local guidelines and the patient’s clinical profile. Harvoni is not an antibiotic; it is an antiviral combination. Treatment planning requires assessment of cirrhosis status, kidney function, and drug interactions. Consistent dosing and clinician follow-up directly impact outcomes.